by Madaline Spencer | Apr 30, 2025
The U.S. Food and Drug Administration (FDA) has approved Zevaskyn (prademagene zamikeracel or pz-cel) for the treatment of wounds in patients with recessive dystrophic epidermolysis bullosa (EB). EB is a group of rare genetic skin diseases that cause the skin to...
by Madaline Spencer | Apr 29, 2025
The U.S. Food and Drug Administration (FDA) has approved nivolumab plus ipilimumab for first-line therapy in adult patients with unresectable or metastatic hepatocellular carcinoma (HCC). HCC is a rare carcinoma of the liver characterized by nodules occurring anywhere...
by Madaline Spencer | Apr 24, 2025
A new study published in American Journal of Hematology compared two treatment options for Graft versus host disease (GVHD). Graft Versus Host Disease GVHD is a rare complication that can occur after a stem cell or bone marrow transplant. It is caused by the newly...
by Madaline Spencer | Apr 23, 2025
Sindhu Ramchandren, MD, Executive Medical Director, Neuroscience and Disease Cluster Lead for Neuroimmunology and Neuromuscular Disorders at Johnson & Johnson, discusses updated results from the Vivacity-MG3 clinical trial in patients with generalized myasthenia...
by Madaline Spencer | Apr 22, 2025
A recent study published in Liver International analyzed patients with primary biliary cholangitis (PBC) who presented with higher IgG levels at diagnosis. Primary Biliary Cholangitis PBC is a chronic, progressive liver disease in which the bile ducts become...
